Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Arrowhead Pharmaceuticals Corp (ARWR) Misses Q1 EPS by 41c, Revenues Miss
February 7, 2019 4:02 PM ESTArrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q1 EPS of $0.13, $0.41 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $34.66 million versus the consensus estimate of $71.6 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
... More